In 2013, US start-up Berg was asked by the Department of Defence to help improve the detection of prostate cancer, a disease which is common among pilots. Less than five years later, an artificial intelligence-driven tool has been tested on over a 1,000 patients with promising results.
Excitement about AI, machine learning and big data have prompted a boom in health-tech start-ups in a market traditionally dominated by big pharma.
Despite debate over the extent to which AI will revolutionise medical science, billions are being bet on something revolutionary emerging to drive the next big leap forward in drug development
As of 30th June 2016, Frontier IP Group Plc (LON:FIPP) have a 5% holding in Exscientia.